2021
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR statusEvaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis
McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis. Cancer 2021, 127: 2409-2422. PMID: 33793971, DOI: 10.1002/cncr.33516.Peer-Reviewed Original ResearchConceptsIndividual patient dataEndometrial cancerPOLE mutationsAdjuvant treatmentAdverse eventsSalvage rateClinical outcomesMeta-analyses (PRISMA) reporting guidelinesConcerns of overtreatmentPathogenic POLE mutationsPatient dataEvidence of diseaseRecurrence/progressionTraditional prognostic factorsProgression/recurrenceUnfavorable pathological featuresAssociation of treatmentMixed effects Cox modelPreferred Reporting ItemsAdditional therapyAdjuvant therapyLess therapyPrognostic factorsFirst diagnosisPathological featuresQuality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal Of The National Cancer Institute 2021, 113: 1369-1378. PMID: 33729494, PMCID: PMC8486331, DOI: 10.1093/jnci/djab034.Peer-Reviewed Original ResearchConceptsLong-term survivorsShort-term survivorsQuality of lifeOvarian cancer survivalLong-term survivalAdverse eventsCancer survivalBaseline QOLCancer Therapy-OvarianTrial Outcome IndexMeaningful prognostic valueLongitudinal mixed modelsAE gradeRobust prognosticatorPatient characteristicsPrognostic valueQoL changesSurvivor groupGOG 218Prognostic relationshipOutcome indexTrial designFunctional assessmentCare implicationsChange scores
2020
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study
Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemoradiotherapy, AdjuvantCystadenocarcinoma, SerousFemaleFollow-Up StudiesHumansHysterectomyImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProgression-Free SurvivalReceptor, ErbB-2Retrospective StudiesRisk AssessmentUnited StatesUterine NeoplasmsUterusConceptsHuman epidermal growth factor 2Uterine serous carcinomaHER2-positive tumorsEarly-stage diseaseOverall survivalSerous carcinomaCohort studyHER2 positivityPositive tumorsEarly stage uterine serous carcinomaLymph-vascular space invasionRecurrent uterine serous carcinomaMulti-institutional cohort studyHuman epidermal growth factor receptor 2Multi-center cohort studyEpidermal growth factor receptor 2Epidermal growth factor 2HER2-positive cohortGrowth factor receptor 2HER2-negative tumorsEquivocal IHC resultsFactor receptor 2Inferior PFSAdjuvant therapyGrowth factor 2
2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Annals Of Oncology 2019, 30: 1080-1087. PMID: 31046082, DOI: 10.1093/annonc/mdz135.Peer-Reviewed Original ResearchConceptsRecurrent ovarian cancerObjective response rateDisease control rateProgression-free survivalTreatment-free intervalDuration of responseAdvanced recurrent ovarian cancerPD-L1 expressionPlatinum-free intervalCohort AOverall survivalPrior linesCohort BOvarian cancerHigh PD-L1 expressionLow objective response rateMedian DORSolid Tumors version 1.1End pointGynecologic cancer-related deathBlinded independent central reviewSafety of pembrolizumabSingle-agent pembrolizumabMedian overall survivalPhase II studyGOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology 2019, 153: 335-342. PMID: 30827726, PMCID: PMC6486855, DOI: 10.1016/j.ygyno.2019.02.028.Peer-Reviewed Original ResearchConceptsProgression-free survivalLymph node metastasisHazard ratioOverall survivalNode metastasisSingle nucleotide polymorphismsOdds ratioNRG Oncology/Gynecologic Oncology Group studyG alleleGynecologic Oncology Group studyEndometrioid endometrial cancer patientsGynecologic Oncology GroupEndometrial cancer patientsPrognostic clinical variablesWorse OSOncology GroupEEC patientsEndometrial cancerNodal metastasisPrimary outcomeClinical outcomesRisk stratificationWashington University SchoolClinical variablesCancer patientsTen-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence
2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal Of Experimental & Clinical Cancer Research 2017, 36: 63. PMID: 28482906, PMCID: PMC5422964, DOI: 10.1186/s13046-017-0536-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Ovarian EpithelialCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticCystadenocarcinoma, SerousDisease ProgressionDNA RepairDrug Resistance, NeoplasmFemaleForkhead Box Protein M1Gene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansKaplan-Meier EstimateMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProtein IsoformsRNA, Small InterferingConceptsForkhead box M1FOXM1 expressionEOC cell linesSerous EOCNormal controlsEOC subtypesCox proportional hazards analysisWorse disease-specific survivalEpithelial ovarian cancer patientsCell linesPlatinum-resistant casesSnap-frozen biopsiesDisease-specific survivalPlatinum-resistant diseaseAdvanced FIGO stageProportional hazards analysisProtein overexpressionClinic-pathological parametersOvarian cancer patientsRT-qPCRTransient siRNA transfectionPARP inhibitor olaparibFIGO stageSerous histologySpecific survival
2016
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesCyclin ECystadenocarcinoma, SerousEndometrial NeoplasmsEpothilonesExomeFemaleHumansMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalOncogene ProteinsPrognosisProtein Kinase InhibitorsProtein Phosphatase 2RadioimmunotherapyReceptor, ErbB-2Sequence Analysis, DNASignal TransductionTOR Serine-Threonine KinasesTubulin ModulatorsTumor Suppressor Protein p53Uterine NeoplasmsVascular Endothelial Growth Factor AConceptsUterine serous carcinomaEndometrial cancerSerous carcinomaTreatment of USCPIK3CA/AKT/mTOREndometrial cancer casesRecent whole-exome sequencing studiesHER2/neu geneNovel therapeutic targetAkt/mTORBiologic therapyAggressive variantDismal prognosisAggressive subtypeWhole-exome sequencing studiesCancer casesTherapeutic targetSubsequent deathDriver mutationsNeu geneGain of functionCarcinomaTherapyCancerSequencing studies
2015
Immunotherapy and targeted therapy for cervical cancer: an update
Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Review Of Anticancer Therapy 2015, 16: 83-98. PMID: 26568261, DOI: 10.1586/14737140.2016.1121108.Peer-Reviewed Original ResearchConceptsCervical cancer patientsCervical cancerCancer patientsImmune check pointsUse of immunotherapyMetastatic cervical cancerPrognosis of patientsActionable driver mutationsTyrosine kinase inhibitorsImmune system interactionsImmunotherapy studiesMedian survivalAngiogenesis inhibitorsChemotherapeutic drugsPatientsDriver mutationsKinase inhibitorsNew therapeuticsCancerNext-generation sequencingImmunotherapyTherapyGeneration sequencingInhibitorsPrognosis
2014
Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging
Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedAged, 80 and overBody Mass IndexCarcinosarcomaCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyLymph Node ExcisionLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesRoboticsSurvival RateConceptsBody mass indexRecurrence-free survivalRobotic-assisted stagingEndometrial cancerRecurrence rateDisease recurrenceMass indexMean postoperative hospitalizationLymph node countMean operative timeLong-term outcomesNonendometrioid cancersMorbid obesityPostoperative hospitalizationMetastatic diseaseNonendometrioid histologyObese patientsOverall survivalConsecutive patientsOperative outcomesHistologic subtypeOperative timeSurgical outcomesEndometrioid carcinomaMean age
2013
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryNeoadjuvant TherapyOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTubulinTumor MicroenvironmentUp-RegulationConceptsClass III β-tubulinIII β-tubulinClass III β-tubulin expressionNeoadjuvant chemotherapyPoor overall survivalOverall survivalΒ-tubulin expressionClass III β-tubulin overexpressionPrimary cytoreductionNeoadjuvant carboplatin/paclitaxelPoor median overall survivalTumor microenvironmentAdvanced ovarian carcinomaCarboplatin/paclitaxelMedian overall survivalOvarian cancer patientsCell linesCancer stem cellsNeoadjuvant carboplatinPrimary debulkingVitro chemosensitivityClinical outcomesPatient populationCancer patientsStromal expressionSecretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis
Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal Of Translational Medicine 2013, 11: 162. PMID: 23819652, PMCID: PMC3706350, DOI: 10.1186/1479-5876-11-162.Peer-Reviewed Original ResearchConceptsOvarian carcinomaNormal ovariesMammaglobin APrognostic markerLipophilin ALipophilin BPatients' clinico-pathological featuresMultivariate Cox regression analysisMammaglobin B mRNANeoplastic ovarian tissuesProgression-free survivalDisease-free survivalProtein expressionCox regression analysisLow tumor gradeClinico-pathological featuresIndependent prognostic markerUnivariate survival analysisOvarian carcinoma samplesAggressive tumor phenotypeGene overexpressionParaffin-embedded tumorsConclusionsThe present studyReal-time reverse transcription PCRQuantitative real-time reverse transcription PCRTubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones
Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119: 2582-2592. PMID: 23585021, PMCID: PMC3700638, DOI: 10.1002/cncr.28017.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmEpothilonesFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedNeoplasm StagingPaclitaxelPlatinum CompoundsPredictive Value of TestsPrognosisReal-Time Polymerase Chain ReactionTubulinTubulin ModulatorsUp-RegulationUterine NeoplasmsConceptsUterine serous carcinomaOvarian serous carcinomaOverall survivalSerous carcinomaP-glycoproteinClinical outcomesPaclitaxel resistanceTreatment of USCPlatinum/taxane chemotherapyPoor overall survivalFresh frozen tissue samplesReal-time polymerase chain reactionCell linesTaxane chemotherapyEndometrial cancerPoor outcomePoor prognosisPolymerase chain reactionFresh frozen tissueMedian inhibitory concentrationClinical investigationSubset of individualsGlycoprotein expressionCarcinomaImmunohistochemistryClass III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal Of Obstetrics And Gynecology 2013, 209: 62.e1-62.e9. PMID: 23583215, DOI: 10.1016/j.ajog.2013.04.017.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cell LineCystadenocarcinoma, SerousDose-Response Relationship, DrugDown-RegulationDrug Resistance, NeoplasmEpothilonesFemaleHumansImmunohistochemistryKaplan-Meier EstimateMicrotubulesNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTaxoidsTubulinTubulin ModulatorsConceptsClass III β-tubulinClear cell carcinomaIII β-tubulinCell carcinomaOverall survivalP-glycoproteinClass III β-tubulin overexpressionClinical outcomesPolymerase chain reactionPaclitaxel resistanceClass III β-tubulin expressionPlatinum/taxane chemotherapyPoor overall survivalSerous papillary carcinomaChain reactionOvarian clear cellFresh frozen tissue samplesReal-time polymerase chain reactionCell linesTime polymerase chain reactionPolymerase chain reaction resultsΒ-tubulin expressionTaxane chemotherapyPoor outcomePoor prognosis
2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal Of Cancer 2012, 106: 1543-1550. PMID: 22531721, PMCID: PMC3341945, DOI: 10.1038/bjc.2012.132.Peer-Reviewed Original ResearchAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityCD55 AntigensCD59 AntigensComplement ActivationCystadenocarcinoma, SerousCytotoxicity, ImmunologicDown-RegulationFemaleFlow CytometryHumansIn Situ Hybridization, FluorescenceMembrane Cofactor ProteinMiddle AgedPrognosisReal-Time Polymerase Chain ReactionReceptor, ErbB-2RNA, Small InterferingTrastuzumabUterine Cervical Neoplasms
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatientsSerum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management
Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2496-2506. PMID: 22028406, PMCID: PMC3237732, DOI: 10.1158/1055-9965.epi-11-0635.Peer-Reviewed Original ResearchConceptsHuman epididymis protein 4Epithelial ovarian cancerSerum human epididymis protein 4Independent prognostic factorOvarian Malignancy AlgorithmPrognostic factorsMalignancy AlgorithmProgression-free survivalLymph node involvementOvarian cancer managementPreoperative serum samplesProtein 4Ovarian benign cystsElevated CA125Node involvementPositive cytologyPostmenopausal womenPremenopausal womenMultivariable analysisMulticenter studyPrognostic valueAdvanced ageOvarian cancerBenign cystsObstetricians stage
2010
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal Of Cancer 2010, 46: 944-953. PMID: 20060709, DOI: 10.1016/j.ejca.2009.12.019.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerTrop-2 overexpressionTrop-2 expressionOverall survivalPrognostic factorsProtein overexpressionTrop-2 protein expressionMultivariate Cox regression analysisConventional clinicopathological featuresPresence of ascitesCox regression analysisLymph node metastasisOvarian carcinoma patientsPoor overall survivalIndependent prognostic markerNovel prognostic factorUnivariate survival analysisAggressive malignant phenotypeImmunotherapeutic strategiesShort-term cultureCarcinoma patientsClinical courseNode metastasisClinicopathological featuresPrognostic significance
2009
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD. Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 2009, 9: 253. PMID: 19635143, PMCID: PMC2724548, DOI: 10.1186/1471-2407-9-253.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerEOC patientsMammaglobin BFresh-frozen tissue biopsiesMultiple histological subtypesDisease-free survivalLong-term prognosisAdditional prognostic informationRisk of recurrenceIndependent prognostic markerIndependent prognostic valueProtein levelsUnivariate survival analysisCancer-related deathAggressive tumor behaviorNormal ovarian controlsPrimary surgeryClinicopathologic characteristicsDisease recurrencePrognostic factorsClinical outcomesClinicopathologic featuresDecreased riskHistological subtypes